La vendita allo scoperto per LENZ Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di LENZ Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

LENZ Therapeutics (NASDAQ:LENZ) Azioni, Report sulle vendite allo scoperto

LENZ Therapeutics

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

LENZ Therapeutics Inc

LENZING AG U/ADR by Lenzing AG

Lenzing AG

B of A Securities analyst Omar Dessouky maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $252 to $375.

News

Price Target

Analyst Ratings

B of A Securities Maintains Buy on AppLovin, Raises Price Target to $375

Elon Musk recently set social media abuzz with a tweet featuring a clip from Netflix&#8217;s &#8220;Narcos,&#8221; where Pablo Escobar, portrayed by actor Wagner Moura, is seen smoking a joint. Musk captioned the post, &#8220;Actual footage of me after @realDonaldTrump won,&#8221; referring to <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">Donald Trump&#8217;s 2024 victory</a>. The tweet&#8217;s provocative nature, tying a drug kingpin character to a political celebration, triggered a range of reactions online.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Actual footage of me after <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> won <a href="https://t.co/PhPJjzaw0J">pic.twitter.com/PhPJjzaw0J</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860475842800812347?ref_src=twsrc%5Etfw">November 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Musk's Cannabis Advocacy And Public Persona</h3>
Musk's selection of a cannabis-themed scene aligns with his public stance on marijuana and psychedelics. In 2018, Musk famously smoked a joint during a live appearance on &#8220;The Joe Rogan Experience,&#8221; sparking both cultural fascination and corporate scrutiny. The incident even prompted NASA to review SpaceX's workplace practices.
Beyond this, Musk has consistently supported the legalization of <a href="https://www.benzinga.com/cannabis">cannabis</a> and the therapeutic use of <a href="https://www.benzinga.com/topic/psychedelics">psychedelics</a>, recently describing them as "pretty helpful" for conditions like PTSD and depression. His tweet juxtaposes this advocacy with a tongue-in-cheek nod to cannabis culture, though some critics have questioned the appropriateness of invoking Escobar&#8217;s likeness in the context of drug reform.
<h3 class="wp-block-heading">Musk's Role In Trump's Reelection And Political Context</h3>
The tweet coincides with Musk's increasing prominence in U.S. politics. As co-leader of the Department of Government Efficiency (DOGE), a special initiative within President-elect Donald Trump's upcoming administration, Musk is tasked with identifying waste in federal operations and driving cost-cutting measures.
See also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41951578/trump-taps-cannabis-supporters-elon-musk-vivek-ramaswamy-to-slash-government-spending">Trump Taps Cannabis Supporters Elon Musk, Vivek Ramaswamy To Slash Government Spending</a>
The role cements Musk's alignment with Trump's deregulatory platform, but his cannabis-friendly public image contrasts sharply with conservative perspectives on drug policy.
<h3 class="wp-block-heading">Wagner Moura's Political Views And Social Media Irony</h3>
Wagner Moura, the Brazilian actor known for his portrayal of Escobar in &#8220;Narcos,&#8221; holds progressive political views that contrast with Musk's alignment with Trump. Moura has openly <a href="https://www.yahoo.com/entertainment/wagner-moura-chasing-truth-100000406.html?utm_source=chatgpt.com&amp;guccounter=1&amp;guce_referrer=aHR0cHM6Ly9jaGF0Z3B0LmNvbS8&amp;guce_referrer_sig=AQAAAHyPGwAKPhq_ebbbAr72fKnwcPnvJS6EpQAlbqiXcPZejVhUfydhaxYD39x4-d1Xi4IZ9CYMdVNt30qS4HKVbbOP2T71GtilDmAimDnHraRNLm8zAuS3LxtiLjwBvSDS9Veg3PKX0XNT33KTYuXeq4qsqFCIZYHrN8nkqE3v-2vh">supported</a> leftist causes in Brazil and has been an outspoken critic of authoritarianism. While he has not directly criticized Trump on record, his advocacy for democratic values and opposition to leaders like Brazil's former president Jair Bolsonaro suggest ideological differences with Trump's approach.
This clash between Moura and Musk was not lost on social media. One Twitter user noted, "This actor is Brazilian. He hates Donald Trump and loves Fidel Castro," while another added, "This actor is Brazilian, liberal, and deeply hates you, Elon." Moura has not publicly commented on the incident, but the online reactions pointed out the irony of Musk's use of the clip
Photo by <a href="https://commons.wikimedia.org/wiki/User:Dmoberhaus">Daniel Oberhaus</a> via <a href="https://commons.wikimedia.org/wiki/File:Elon_Musk_at_a_Press_Conference.jpg">Wikimedia Commons</a>, edited by Benzinga

Cannabis

Social Media

Politics

Did Elon Musk Really Use A Meme Of Pablo Escobar Smoking Weed To Celebrate Trump's Election Victory? What Does It Even Mean?

WIIM

QNTM

Quantum BioPharma shares are trading higher after the company announced legal teams have been assembled to pursue the recovery of all losses and damages.

RBC Capital analyst Christopher Dendrinos maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Outperform and raises the price target from $285 to $376.

RBC Capital Maintains Outperform on GE Vernova, Raises Price Target to $376

UPXI

Upexi shares are trading lower. The company filed litigation in Nevada in determining manipulation of fractional share roundups during its reverse stock split.

JMP Securities analyst Andrew Boone maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Market Outperform and raises the price target from $118 to $160.

RDDT

JMP Securities Maintains Market Outperform on Reddit, Raises Price Target to $160

Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares traded higher after the company signed <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42161696/vast-receives-30m-from-australian-renewable-energy-agency-for-green-technology-to-decarbonise-aust" rel="noreferrer noopener">an updated funding agreement</a>.
The agreement will give access up to $30 million of its $65 million grant from the Australian Renewable Energy Agency.
The funding will support Vast&#8217;s green technology manufacturing and project development, enabling the deployment of its next-generation concentrated solar thermal power (CSP) solution to provide clean, dispatchable power and heat.
Vast has developed next-generation proprietary CSP technology, offering superior performance at lower cost and risk.
The company has a global project pipeline aimed at decarbonizing electricity generation and powering green methanol and sustainable aviation fuel production.
Proven at its pilot project in New South Wales, Vast&#8217;s technology is set for utility-scale deployment at Vast Solar 1 (VS1), a 30MW power plant with 8 hours of storage in South Australia&#8217;s Port Augusta Green Energy Hub.
The Port Augusta CSP project will generate clean, dispatchable electricity for the National Electricity Market and power Solar Methanol 1 (SM1), a world-first green methanol production facility.
Vast&#8217;s Australian-made CSP technology, produced at its Queensland facility, will benefit from $30 million in funding from ARENA.
This will support the scaling of manufacturing for VS1 and future projects, as well as final development activities ahead of the Final Investment Decision in early 2025.
The funding is expected to create green manufacturing, construction, and long-term operations jobs.
Construction of VS1 is expected to start in the second quarter of 2025, with capital expenditures estimated between A$360 million and A$390 million.
CEO Craig Wood emphasized that the Australian Government support positions Vast to lead a domestic CSP industry and expand its global project pipeline.
Price Action: VSTE shares are up 30.4% at $2.151 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42165679" target="_blank" rel="noreferrer noopener">Nio Analyst Sees Tougher Path To Profitability, Downgrades EV Maker To Sell: What You Need To Know</a></li>
</ul>
Image via Unsplash.

Equities

Small Cap

Movers

VSTE

Vast Renewables Powers Up: $30M Funding Fuels Australia's Next-Gen Solar And Methanol Breakthrough

Wells Fargo analyst Zachary Fadem maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Overweight and lowers the price target from $325 to $320.

TSCO

Wells Fargo Maintains Overweight on Tractor Supply, Lowers Price Target to $320

Trading Ideas

SMTK

SmartKem Shares Resume Trade Then Again Halt On Circuit Breaker To The Downside, Stock Now Up 21.9%

BMO Capital analyst Rufus Hone downgrades Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) from Outperform to Market Perform and raises the price target from $94 to $100.

Downgrades

BMO Capital Downgrades Block to Market Perform, Raises Price Target to $100

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>)(CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>)(CSE:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#CSE">HUGE</a>) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the extent determined by the courts. As a result, prominent legal teams have been assembled to pursue the recovery of all losses and damages impacting our Company. The law firms have agreed to be compensated without cost to the Company but solely on a contingency basis, meaning that the Company will not be billed for legal costs in this matter. The Company itself is seeking damages of more than US$700M we believe it has suffered. The shareholders can find updated information about the case on the <a href="https://stats.nwe.io/x/html?final=aHR0cHM6Ly93d3cucXVhbnR1bWJpb3BoYXJtYS5jb20vcXVhbnR1bS1iaW9waGFybWEtdnMtYmFua3M&amp;sig=5qokejQshKBtsyGPvETI3Dajx81D1ik76d53wt2_oHIhWuBBsy7ShTs5WoWCxoDKswAzLDh_haIgDwdUYAVTNw&amp;hit%2Csum=WyI0bmM0YXEiLCI0bmM0YXIiLCI0bmM0YXMiXQ">Quantum vs Banks</a> page of our website which will be updated periodically.
Quantum Biopharma previously know as FSD Pharma and traded under the symbol HUGE is inviting and requesting shareholders to join with the company in its quest to get justice for itself and all affected shareholders, both past and current. The company strongly believes the more affected and harmed shareholders that come forward to share specific details of their losses, the stronger the case will become against the alleged perpetrators, for the vast financial harm they have caused.

Short Sellers

Legal

Management

CSE:HUGE

CSE:QNTM

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

Quantum BioPharma Invites Shareholders To The $700M+ Court Case The Company Has Filed Against CIBC, RBC, And Others For Alleged Spoofing/Stock Price Manipulation

Wells Fargo analyst Stephen Baxter maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Overweight and lowers the price target from $285 to $230.

Wells Fargo Maintains Overweight on Universal Health Servs, Lowers Price Target to $230

Agreement Expands EzFill's Operations to Four New States
Deal Expected to Close December 2
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- EzFill Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZFL#NASDAQ">EZFL</a>), a leading mobile fueling company, has signed a definitive agreement to acquire the fueling division of Yoshi, Inc. with the aim of expanding its U.S operations and presence.
Under the terms of the agreement, EzFill will acquire Yoshi Mobility's existing mobile fuel service assets and allows EzFill to begin operations in four new states: California, Tennessee, Texas, and Michigan. EzFill will integrate Yoshi's assets, operations and customers into its growing infrastructure. With this acquisition, EzFill plans to not only strengthen the company's footprint in its existing markets but also take advantage of EzFill's national customers and begin offering services to them in those markets. EzFill will immediately add diesel fueling to the services currently offered by Yoshi in those markets which the Company believes will immediately increase revenues in those areas. Additionally, EzFill hopes to initiate an aggressive national expansion plan, positioning itself as a leading player in the on-demand fueling sector.

EZFL

EzFill Signs Definitive Agreement For The Purchase Of Yoshi Mobility's Fuel Division, Agreement Expands Operations To Four New States; Deal Expected To Close December 2; No Financial Terms Disclosed

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), the heavyweight of Big Tech, has hit a grim milestone in technical analysis: <a href="https://www.benzinga.com/topic/death-cross">a Death Cross</a>. 
With its share price slipping below key moving averages, MSFT stock has moved into bearish territory, casting doubts on its near-term prospects. Is this just a blip for the software giant, or the prelude to deeper woes?
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM.png" alt="" class="wp-image-663339" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">MSFT Stock: Bearish Signals All Around</h2>
At $418.19, MSFT stock price trails its 20-day, 50-day and even the 200-day simple moving averages (SMAs). Technical indicators are sounding alarms:
<ul>
<li>The 20-day SMA at $418.73, the 50-day SMA at $421.65 and the 200-day SMA at $421.81 all point to a bearish signal.</li>
<li>The eight-day SMA at $417.37, continues to be driven by bullish sentiment over the short term, driven by buying pressure.</li>
<li>The Moving Average Convergence Divergence (MACD) stands at -1.11, another red flag.</li>
<li>The Relative Strength Index (RSI) at 49.09 suggests that Microsoft isn't oversold yet but is heading toward bearish momentum.</li>
</ul>
These technical markers paint a strongly bearish picture. Yet, buying pressure persists, indicating that investors still see potential for a turnaround—a glimmer of bullish hope amidst the gloom.
Read Also: <a href="https://www.benzinga.com/24/11/42160614/microsoft-ceo-satya-nadella-calls-for-culture-change-after-security-breaches-that-led-to-voluntary-pay-cut">Satya Nadella Promises &#8216;Culture Change&#8217; After Security Lapses Return To Haunt Microsoft 20 Years After Bill Gates Launched A Similar Initiative</a>
<h2 class="wp-block-heading">The ProPublica Bombshell</h2>
Compounding Microsoft's technical woes is a ProPublica investigation that has raised ethical and legal concerns over the company&#8217;s federal contracting practices. As detailed in the <a href="https://www.propublica.org/article/microsoft-white-house-offer-cybersecurity-biden-nadella">report</a>, Microsoft's "White House Offer"—a supposedly altruistic pledge to bolster government cybersecurity—was a calculated business maneuver. 
The plan involved providing free upgrades and consulting services to federal agencies, locking them into Microsoft's ecosystem. Once the "free" period ended, agencies had little choice but to continue with costly subscriptions and Azure services, effectively squeezing out competitors.
This strategy not only strengthened Microsoft's grip on federal business but also invited scrutiny for potentially violating federal procurement and antitrust laws. Legal experts argue that the deal sidesteps open competition, raising concerns about its long-term implications for government reliance on a single vendor.
<h2 class="wp-block-heading">A Double-Edged Sword</h2>
While the technical indicators signal bearishness, the buying pressure suggests a tug-of-war between short-term skepticism and long-term optimism. Microsoft's market dominance—bolstered by its lucrative cloud business and strategic maneuvers—remains a formidable moat. 
However, the ethical controversies surrounding its federal contracts could dent investor confidence and invite regulatory headwinds.
<h2 class="wp-block-heading">The Verdict</h2>
Microsoft's Death Cross is a wake-up call for investors. With the stock under technical pressure and the ProPublica revelations casting a shadow over its business practices, the path forward is murky. 
Bulls might see this as a chance to buy on weakness, banking on Microsoft's resilience. Bears, however, have a compelling case to remain cautious as the stock navigates this precarious juncture.
For now, Microsoft's crossroads is a reminder that even the mightiest of tech giants are not immune to scrutiny—or the market's harsh judgment.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/24/11/42136902/microsofts-brad-smith-urges-trump-government-to-tackle-growing-cyber-threats">Microsoft&#8217;s Brad Smith Urges Trump Government to Tackle Growing Cyber Threats</a></li>
</ul>
Image: Shutterstock

Long Ideas

Technicals

Signals

Tech

MSFT

Microsoft's Death Cross: Tech Giant Faces A Double Blow With FTC Pressure

SmartKem Shares Halted On Circuit Breaker To The Downside, Stock Now Up 39.4%

<a href="https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales" title="https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales">https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales</a>

AAPL

"Apple's Thin iPhone Has No Physical SIMs—That Could Dampen China Sales" - The Information

JMP Securities analyst Jordan Bender maintains MGM Resorts Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Market Outperform and lowers the price target from $54 to $50.

JMP Securities Maintains Market Outperform on MGM Resorts Intl, Lowers Price Target to $50

Macro Economic Events

Econ #s

Economics

Dallas Fed Manufacturing Business Index For November -2.7 Vs -2.4 Est.; -3.0 Prior

William Blair analyst Jeff Schmitt initiates coverage on Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform rating.

Initiation

NDAQ

William Blair Initiates Coverage On Nasdaq with Outperform Rating

In the current session, the stock is trading at $116.06, after a 0.36% increase. Over the past month, Walt Disney Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) stock increased by 21.08%, and in the past year, by 25.83%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732548611_0.png" alt="Past Year Chart" />

<h3>Walt Disney P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Walt Disney has a lower P/E than the aggregate P/E of 52.76 of the Entertainment industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732548611_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Walt Disney

LENZ reports positive Chinese study data for far-sightedness drug

In a report released yesterday, Marc Goodman from Leerink Partners maintained a Buy rating on LENZ Therapeutics (LENZ – Research Report). The compa...

Leerink Partners Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
LENZ Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/lenz-stock-quote/">LENZ</a>) just reported results for the first quarter of 2024.<ul><li>LENZ Therapeutics reported earnings per share of -$3.53. This was below the analyst estimate for EPS of -84 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/lenz-stock-earnings-lenz-therapeutics-for-q1-of-2024/">LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024

LENZ Therapeutics GAAP EPS of -$0.38

LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript

Leerink raised the firm's price target on Lenz Therapeutics (LENZ) to $36 from $32 and keeps an Outperform rating on the shares after the company r...

Lenz Therapeutics price target raised to $36 from $32 at Leerink

Lenz Therapeutics, Inc. (LENZ) has disclosed a new risk, in the Trade Secrets category. Lenz Therapeutics, Inc. faces significant business risks re...

Patent Challenges Threaten Lenz Therapeutics' Market Strategy and Financial Stability

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on LENZ Therapeutics (LENZ – Research Report) today and set a price target of $38....

Positive Buy Rating for LENZ Therapeutics' LNZ100 Eye Drop Amid Promising Clinical Results and Market Differentiation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
LENZ Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/lenz-stock-quote/">LENZ</a>) just reported results for the first quarter of 2024.<ul><li>LENZ Therapeutics reported earnings per share of -$3.53. This was below the analyst estimate for EPS of -84 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/lenz-stock-earnings-lenz-therapeutics-for-q1-of-2024/">LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Comments

LENZ Therapeutics

Vendite allo scoperto

LENZ Therapeutics (NASDAQ:LENZ) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO